New COPD Drug Tozorakimab Shows Promising Results in Clinical Trials

A new biological drug, Tozorakimab, is offering hope for patients with Chronic Obstructive Pulmonary Disease (COPD), a progressive lung disease that significantly hinders breathing. Recent Phase 3 clinical trials, presented at the European Respiratory Society (ERS) Congress and published in the New England Journal of Medicine, demonstrated that adding Tozorakimab to standard treatment reduced moderate to severe exacerbations by 29% to 43% compared to a placebo. These results are considered particularly significant given the limitations of existing biological treatments.

COPD, often caused by smoking, air pollution, or occupational dust, leads to emphysema and inflamed airways, resulting in shortness of breath, coughing, and mucus production. Exacerbations, or sudden worsening of symptoms, are life-threatening and accelerate disease progression. Dr. Amir Bar-Shai, head of the Pulmonology Institute at Ichilov Hospital in Tel Aviv and a lead researcher in Israel, highlighted that standard treatments often fail to prevent these exacerbations, with up to 70% of patients on triple inhaled therapy experiencing at least one per year.

Despite its prevalence and severity, COPD is described as a "silent epidemic," with an estimated 2,000 to 3,000 deaths annually in Israel, though the actual number may be higher due to deaths being attributed to secondary infections or cardiovascular events. The disease also imposes a significant economic burden, costing between $1,500 and $2,500 per patient annually in Israel, with approximately 300,000 people affected. Dr. Bar-Shai also noted a societal stigma against COPD patients, particularly smokers, who are sometimes perceived as deserving of their condition rather than receiving full medical sympathy.

While existing biological treatments for COPD have shown a 20-30% reduction in exacerbations, they are typically limited to patients with high eosinophil counts. Tozorakimab, which works by blocking the IL-33 protein, a key early signal in the immune system's response to airway damage, has shown efficacy across a broader patient population, including those with lower eosinophil levels. The OBERON and TITANIA trials involved over 2,300 patients, and results indicated a 29-34% reduction in exacerbations for former smokers and a 30% reduction for current smokers. Even in patients with less than 150 eosinophils per microliter, the drug reduced exacerbations by 23%, rising to 43% in those with 300 or more.

Israeli medical centers, including Ichilov Hospital, participated in the trials, treating 60 patients. Researchers observed positive effects and a favorable safety profile with minor side effects. Tozorakimab has received Fast Track designation from the U.S. Food and Drug Administration (FDA) to expedite its development. However, it is not yet approved by regulators in any country, including Israel. The key challenge moving forward will be ensuring patient access to this potentially life-changing, though likely expensive, treatment.